15 Feb 2013, BioSpectrum Bureau , BioSpectrum
Bangalore: India-based Kemwell Biopharma appointed Dr Ninad Deshpanday as president of R&D. Dr Deshpanday has over 22 years of experience in diverse international roles in the pharmaceutical industry. This includes pharmaceutical development activities for NDAs, specialty drug delivery based 505(b)(2) products, including oral and transdermal, and complex generic products, with several F2Fs and PIVs. He also has rich experience in technical and business development.
Prior to joining Kemwell, he was president of pharmaceutical R&D at Lupin, in Pune, India since November 2007, with leadership responsibilities for formulations, analytical, and BA/BE activities. Before joining Lupin, Dr Deshpanday was vice president of business development at AAIPharma in RTP, US, with responsibilities for sales and marketing activities for their CM and C functions.
He was also VP for drug product development for Synta Pharmaceuticals; and technical business director for the pharmaceutics division of Cardinal Health. Dr Deshpanday earned his doctorate in pharmaceutics from the University of Southern Carolina in 1990, and has an M Pharm. and B Pharm. from LM College of Pharmacy in Ahmedabad, India.
Mr Anurag Bagaria, chairman and managing director, Kemwell, said, "Dr Deshpanday brings a unique combination of leadership skills and technical expertise in pharmaceutical development, as well as excellent business development skills with a very strong network of customers in the US, Europe and Asia. He will spearhead the R&D business for Kemwell as we continue to grow the geographical footprint and strategically position Kemwell into a leading global contract services provider."